Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea
1
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Although coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, the implication of pre-existing liver disease on the outcome of COVID-19 remains unresolved. Methods: A total of 1,005 patients who were admitted to five tertiary hospitals in South Korea with laboratory-confirmed COVID-19 were included in this study. Clinical outcomes in COVID-19 patients with coexisting liver disease as well as the predictors of disease severity and mortality of COVID-19 were assessed. Results: Of the 47 patients (4.7%) who had liver-related comorbidities, 14 patients (1.4%) had liver cirrhosis. Liver cirrhosis was more common in COVID-19 patients with severe pneumonia than in those with non-severe pneumonia (4.5% vs. 0.9%, P=0.006). Compared to patients without liver cirrhosis, a higher proportion of patients with liver cirrhosis required oxygen therapy; were admitted to the intensive care unit; had septic shock, acute respiratory distress syndrome, or acute kidney injury; and died (P<0.05). The overall survival rate was significantly lower in patients with liver cirrhosis than in those without liver cirrhosis (log-rank test, P=0.003). Along with old age and diabetes, the presence of liver cirrhosis was found to be an independent predictor of severe disease (odds ratio, 4.52; 95% confidence interval [CI], 1.20–17.02; P=0.026) and death (hazard ratio, 2.86; 95% CI, 1.04–9.30; P=0.042) in COVID-19 patients. Conclusions: This study suggests liver cirrhosis is a significant risk factor for COVID-19. Stronger personal protection and more intensive treatment for COVID-19 are recommended in these patients.
Abstract
Background/Aims: Although coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, the implication of pre-existing liver disease on the outcome of COVID-19 remains unresolved. Methods: A total of 1,005 patients who were admitted to five tertiary hospitals in South Korea with laboratory-confirmed COVID-19 were included in this study. Clinical outcomes in COVID-19 patients with coexisting liver disease as well as the predictors of disease severity and mortality of COVID-19 were assessed. Results: Of the 47 patients (4.7%) who had liver-related comorbidities, 14 patients (1.4%) had liver cirrhosis. Liver cirrhosis was more common in COVID-19 patients with severe pneumonia than in those with non-severe pneumonia (4.5% vs. 0.9%, P=0.006). Compared to patients without liver cirrhosis, a higher proportion of patients with liver cirrhosis required oxygen therapy; were admitted to the intensive care unit; had septic shock, acute respiratory distress syndrome, or acute kidney injury; and died (P<0.05). The overall survival rate was significantly lower in patients with liver cirrhosis than in those without liver cirrhosis (log-rank test, P=0.003). Along with old age and diabetes, the presence of liver cirrhosis was found to be an independent predictor of severe disease (odds ratio, 4.52; 95% confidence interval [CI], 1.20–17.02; P=0.026) and death (hazard ratio, 2.86; 95% CI, 1.04–9.30; P=0.042) in COVID-19 patients. Conclusions: This study suggests liver cirrhosis is a significant risk factor for COVID-19. Stronger personal protection and more intensive treatment for COVID-19 are recommended in these patients.
참고문헌 (29)
- "Coronavirus disease (COVID-19)Situation Report – 134"[URL]
- Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirusinfected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
- Wang B, "Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis", Aging (Albany NY), 12, pp.6049~6057 (2020)
- Zhang C, "Liver injury in COVID-19 : management and challenges", Lancet Gastroenterol Hepatol, 5, pp.428~430 (2020)
- Asrani SK, "Burden of liver diseases in the world", J Hepatol, 70, pp.151~171 (2019)
- Fernández J, "Management of bacterial infections in cirrhosis", J Hepatol 2012;56 Suppl, 56(Suppl 1), pp.S1~S12 (2012)
- Fernández J, "Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis : a prospective study", Hepatology, 55, pp.1551~1561 (2012)
- Iavarone M, "High rates of 30-day mortality in patients with cirrhosis and COVID-19", J Hepatol (2020)[DOI]
- Qi X, "Clinical course and risk factors for mortality of COVID-19 patients with preexisting cirrhosis: a multicentre cohort study", Gut (2020)[DOI]
- Korean Society of Infectious Diseases, "Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020", Journal of Korean Medical Science, 35(12), pp.1~9 (2020), 대한의학회[DOI]
- "The update of COVID-19 in Korea as of June 3"[URL]
- Korean Society of Infectious Diseases, "Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020", Journal of Korean Medical Science, 35(10), pp.1~11 (2020), 대한의학회[DOI]
- "Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020"[URL]
- "Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection: interim guidance, 10 January 2020"[URL]
- "Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected:interim guidance, 13 March 2020"[URL]
- "KDIGO clinical practice guideline for acute kidney injury"[URL]
- Yeom SK, "Prediction of liver cirrhosis, using diagnostic imaging tools", World J Hepatol, 7, pp.2069~2079 (2015)
- Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
- European Association for the Study of the Liver, "EASL clinical practice guidelines for the management of patients with decompensated cirrhosis", J Hepatol, 69, pp.406~460 (2018)
- Chung W, "The cost of liver disease in Korea : methodology, data, and evidence", Clin Mol Hepatol, 21, pp.14~21 (2015)
- Sun J, "COVID-19 and liver disease", Liver Int, 40, pp.1278~1281 (2020)
- Chai X, "Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection", bioRxiv. 2020 Feb 4. doi: 10.1101, 2020 (2020)
- Albillos A, "Cirrhosis-associated immune dysfunction : distinctive features and clinical relevance", J Hepatol, 61, pp.1385~1396 (2014)
- Bernsmeier C, "Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK", Gastroenterology, 148, pp.603~615. e14 (2015)
- Bernardi M, "Mechanisms of decompensation and organ failure in cirrhosis : from peripheral arterial vasodilation to systemic inflammation hypothesis", J Hepatol, 63, pp.1272~1284 (2015)
- Gacouin A, "Liver cirrhosis is independently associated with 90-day mortality in ARDS patients", Shock, 45, pp.16~21 (2016)
- Ji D, "Implication of non-alcoholic fatty liver diseases(NAFLD)in patients with COVID-19 : a preliminary analysis", J Hepatol, 73, pp.451~453 (2020)